


# From Molecule to Materials to Medicine

## Accelerating the Development Journey Through the Application of Structural Sciences – Feedback on key slides

Get in touch: Andy Maloney, Ghazala Sadiq, Elna Pidcock, Bob Docherty




### Solid Form Selection Decision Tree

1. Do you agree with the overall flowchart? What changes, if any, would you suggest?
2. Do you agree with the weightings in terms of colour (green, blue, orange, red) defining complexity of solid form?
3. Does this flowchart resonate with working practices within your organisation/community? What are the differences?


### Crystallographic Data Thread

1. Do you agree with the key contact points for the crystallographic data thread? Are there others?
2. Which ones are the most important? Which ones would you want to enhance?
3. Is there a better version of this slide that would show the importance of crystallographic information across development?

### The Importance of Crystallographic Studies. A Critical Data Thread Across Drug Development



### Placing Structural Sciences at the Heart of the Materials Sciences Tetrahedron



### CSD and the Mat Sci Tetrahedron

1. What are the key connections to make across the tetrahedron and how would you go about doing that?
2. What are the priorities across Properties, Processing, and Performance? Where should we start?
3. Do you agree with the tapestry that needs to be created? What are the biggest challenges you see for our community?

### Future Perspective

1. What are the key connections to make across the tetrahedron and how would you go about doing that?
2. What are the priorities across Properties, Processing, and Performance? Where should we start?
3. Do you agree with the tapestry that needs to be created? What are the biggest challenges you see for our community?

### Academic Perspective

#### Building on Example From Previous Slide – Future Outlook

- Remains highly topical and challenging.
- Editorial perspectives reaching across different communities.
- Building on existing solid form activities and successes.
- Moving towards drug product with consideration for form in different product types
- Solid form integral to many aspects of drug delivery.
- Through engineering solid form attributes - deliver diversity of dosage forms that meet patients needs.
- 'Stressing why the quest for new crystal forms of any given API can still be both "joy and sorrow" for the academic and industrial researcher.'